Lee S
Trials. 2023; 24(1):745.
PMID: 37990281
PMC: 10664620.
DOI: 10.1186/s13063-023-07793-0.
Takahashi A, Suzuki T
Contemp Clin Trials Commun. 2021; 21:100753.
PMID: 33681528
PMC: 7910500.
DOI: 10.1016/j.conctc.2021.100753.
Burnett T, Mozgunov P, Pallmann P, Villar S, Wheeler G, Jaki T
BMC Med. 2020; 18(1):352.
PMID: 33208155
PMC: 7677786.
DOI: 10.1186/s12916-020-01808-2.
Polley M, Cheung Y
JCO Precis Oncol. 2020; 3.
PMID: 32923846
PMC: 7446322.
DOI: 10.1200/PO.19.00057.
Portnow J, Badie B, Blanchard M, Kilpatrick J, Tirughana R, Metz M
Cancer Gene Ther. 2020; 28(3-4):294-306.
PMID: 32895489
PMC: 8843788.
DOI: 10.1038/s41417-020-00219-y.
Reprioritizing Risk and Benefit: The Future of Study Design in Early-Phase Cancer Research.
Sisk B, DuBois J, Hobbs B, Kodish E
Ethics Hum Res. 2019; 41(6):2-11.
PMID: 31743629
PMC: 7418216.
DOI: 10.1002/eahr.500033.
Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial.
Wang S, Xu X, Yao J, Peng P, Zhou B, Liu Q
Transl Oncol. 2018; 11(4):1007-1011.
PMID: 29966863
PMC: 6039884.
DOI: 10.1016/j.tranon.2018.06.004.
Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.
Hlubocky F, Kass N, Roter D, Larson S, Wroblewski K, Sugarman J
J Oncol Pract. 2018; 14(6):e357-e367.
PMID: 29787333
PMC: 6002254.
DOI: 10.1200/JOP.18.00028.
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial.
von Einem J, Peter S, Gunther C, Volk H, Grutz G, Salat C
Oncotarget. 2017; 8(46):80156-80166.
PMID: 29113291
PMC: 5655186.
DOI: 10.18632/oncotarget.20964.
Safety and tolerability of transcranial direct current stimulation to stroke patients - A phase I current escalation study.
Chhatbar P, Chen R, Deardorff R, Dellenbach B, Kautz S, George M
Brain Stimul. 2017; 10(3):553-559.
PMID: 28279641
PMC: 5411981.
DOI: 10.1016/j.brs.2017.02.007.
Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T
PLoS One. 2017; 12(1):e0170187.
PMID: 28125617
PMC: 5268707.
DOI: 10.1371/journal.pone.0170187.
Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.
Portnow J, Synold T, Badie B, Tirughana R, Lacey S, DApuzzo M
Clin Cancer Res. 2016; 23(12):2951-2960.
PMID: 27979915
PMC: 8843778.
DOI: 10.1158/1078-0432.CCR-16-1518.
Assessing risk/benefit for trials using preclinical evidence: a proposal.
Kimmelman J, Henderson V
J Med Ethics. 2015; 42(1):50-3.
PMID: 26463620
PMC: 4854630.
DOI: 10.1136/medethics-2015-102882.
A statistical evaluation of dose expansion cohorts in phase I clinical trials.
Boonstra P, Shen J, Taylor J, Braun T, Griffith K, Daignault S
J Natl Cancer Inst. 2015; 107(3).
PMID: 25710960
PMC: 4565529.
DOI: 10.1093/jnci/dju429.
A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy.
Peng Y, Liu Y, Ren X, Chen X, Su H, Zong J
Oncol Lett. 2014; 9(1):67-74.
PMID: 25435935
PMC: 4246893.
DOI: 10.3892/ol.2014.2675.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Jotte R, Von Hoff D, Braiteh F, Becerra C, Richards D, Smith D
Invest New Drugs. 2014; 33(1):148-58.
PMID: 25260842
DOI: 10.1007/s10637-014-0160-z.
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M
Invest New Drugs. 2014; 32(5):985-94.
PMID: 24875134
DOI: 10.1007/s10637-014-0118-1.
What does a modified-Fibonacci dose-escalation actually correspond to?.
Penel N, Kramar A
BMC Med Res Methodol. 2012; 12:103.
PMID: 22824322
PMC: 3538691.
DOI: 10.1186/1471-2288-12-103.
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.
Goffin J, Pond G
BMC Med Res Methodol. 2011; 11:164.
PMID: 22151297
PMC: 3259049.
DOI: 10.1186/1471-2288-11-164.
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Algazi A, Weber J, Andrews S, Urbas P, Munster P, DeConti R
Br J Cancer. 2011; 106(1):85-91.
PMID: 22127285
PMC: 3251861.
DOI: 10.1038/bjc.2011.514.
